- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib
This study is comparing a new medicine, fedratinib, with other common treatments for people with a type of bone marrow disorder called myelofibrosis. It's for patients whose myelofibrosis has been treated before with another drug called ruxolitinib. We want to see how well fedratinib shrinks the spleen.
For: Primary myelofibrosis · post-polycythemia vera myelofibrosis · or post-essential thrombocythemia myelofibrosisBelgium · Italy · Hungary - Ongoing, recruitingTherapeutic use (Phase IV)
HU-F-AIM - A prospective, interventional study to evaluate HU-resistance in polycythemia vera patients who meet predictive parameters identified in the machine learning project PV-AIM
This study looks at how well a medicine called hydroxycarbamide works for people with a blood condition called polycythaemia vera. It aims to identify patients who might not respond well to this treatment from the beginning, helping doctors choose the best care.
For: Polycythemia veraGermany - RecruitingPHASE3
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
This study compares a new drug, ruxolitinib, with standard treatments (hydroxycarbamide or interferon) for people with high-risk Polycythaemia Vera. It aims to see which treatment works best as a first approach.
For: Polycythemia VeraUnited Kingdom